Vallon Pharmaceuticals (VLON) IPO Opens Higher

Today's IPO for Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) opened for trading at $9.01 after pricing 2,250,000 shares of its common stock at a public offering price of $8.00 per share.

ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.

Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.

You May Also Be Interested In

• CopperTech Metals launches IPO roadshow on NYSE at $16-$18 per share
• DSC Holdings files for Nasdaq IPO at $16 to $18 per ADS
• Student Living EduVation files for 6.25M share Nasdaq IPO at $4-$6 per share